Malte Lenders

14PUBLICATIONS
1CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biochemistry - amino acids and metabolitesAutoimmunityFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 09, 2026
Impact of SGLT2 inhibitors in patients with Fabry disease.

Malte Lenders, Sima Canaan-Kühl, Christine Kurschat

|Nov 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.

Malte Lenders, Elise Raphaela Menke, Michael Rudnicki

|Sep 29, 2024
Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test?

Malte Lenders, Elise Raphaela Menke, Eva Brand

|Mar 27, 2024
Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.

Malte Lenders, Eva Brand

|May 05, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).

Malte Lenders, Peter Nordbeck, Christine Kurschat

|Jan 29, 2022
Fabry disease - a multisystemic disease with gastrointestinal manifestations.

Malte Lenders, Eva Brand

Pageof 3

Frequent Collaborators

2 joint publications

Peter Nordbeck